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Abstract: In this review, the potential causes of ageing are discussed. We seek to gain insight into
the main physiological functions of mitochondria and discuss alterations in their function and the
genome, which are supposed to be the central mechanisms in senescence. We conclude by presenting
the potential modulating role of the kynurenine pathway in the ageing processes. Mitochondrial
dynamics are supposed to have important physiological roles in maintaining cell homeostasis. During
ageing, a decrease in mitochondrial dynamics was reported, potentially compromising the function
of mitochondria. Mitochondrial biogenesis not only encompasses mitochondrial dynamics, but also
the regulation of transcription and translation of genes, and mitochondria are supposed to play
a prominent role in cell death during senescence. Defects in the mtDNA replication machinery and
failure in the repair of mtDNA might result in the accumulation of mutations, leading to mitochondrial
dysfunction and bioenergetic failure of the cell. The role of reactive oxygen species (ROS) in the ageing
processes is widely acknowledged. Exaggerated oxidative damage to mDNA is supposed to take
place during senescence, including single-nucleotide base alterations, nucleotide base pair alterations,
chain breaks and cross linkage. A broad repertoire for the repair of DNA faults has evolved, but they
do not function efficiently during senescence. Poly (ADP-ribose) polymerase (PARP) is an enzyme
that assists in DNA repair, i.e., it participates in the repair of single-stranded DNA nicks, initiating
base excision repair (BER). In the case of extensive DNA damage, PARP-1 becomes overactivated
and rapidly depletes the intracellular NAD+ and ATP pools. This results in a profound energy loss
of the cell and leads to cell dysfunction, or even cell death. Alterations in the kynurenine system
have been linked with ageing processes and several age-related disorders. The kynurenine pathway
degrades tryptophan (TRP) to several metabolites, among others kynurenine (KYN), kynurenic acid
(KYNA) and quinolinic acid (QUIN). The end product of the route is NAD+. The first metabolic
reaction is mediated by TRP-2,3-dioxygenase (TDO) or indolamine-2,3-dioxygenases (IDO), the latter
being induced by inflammation, and it is thought to have a significant role in several disorders and
in ageing. Research is currently focusing on the KYN pathway, since several intermediates possess
neuro- and immunoactive properties, and hence are capable of modulating the activity of certain
brain cells and inflammatory responses. During ageing, and in many age-associated disorders like
obesity, dyslipidaemia, hypertension, insulin resistance and neurodegenerative diseases, low-grade,
sustained inflammation and upregulation of IDO have been reported. However, TRP downstream
catabolites create a negative feedback loop by weakening the activated immune system through
several actions, including a decline in the Th1 response and an enhancement of Th2-type processes.
The broad actions of the KYN-intermediates in brain excitation/inhibition and their role in regulating
immune responses may provide the possibility of modifying the pathological processes in an array of
age-associated diseases in the future.
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1. Introduction
Researchers have always been interested in the process of ageing and what the “primum movens”
that induces ageing mechanisms truly is. In recent decades, there has been an increasing focus on
mitochondria, as the cell organelle initiating and regulating these metabolic steps plays a crucial role
in ageing. As these cellular actions are thought to constitute the basis of neurodegenerative disorders,
better insight into these mechanisms might open up new therapeutic avenues that promote a longer
lifespan and successfully combat these devastating disorders.
In the current review we seek to gain insight into the main physiological functions of mitochondria
and discuss alterations in their function and the genome, which are supposed to be the central
mechanisms of senescence. We conclude this review by presenting the potential modulating role of the
kynurenine pathway in the aging processes.
2. Normal Function of Mitochondria
Mitochondria are an integral part of the host cells and have an important role in an array
of metabolic processes, including amino acid synthesis, lipid metabolism, energy production, free
radical generation, calcium homeostasis, cell cycle regulation, apoptosis, signalling processes and
thermogenesis. In addition, mitochondria are key components in the process of development, ageing
and even cell death. Last but not least, mitochondria play a dominant role in neurodegeneration [1].
Mitochondria are considered highly versatile organelles that are capable of changing their morphology,
number, location within the cell, as well as their function under certain conditions, either caused
by physiological stimuli, or diverse stressors such as hormones, diet, temperature and exercise [2].
Mitochondria are regarded as the powerhouse of the cell, as the majority of metabolic processes occur
within the mitochondria, which ultimately converge to form acetyl-coenzyme A (acetyl-CoA) [3].
The main energy substrate of the brain is glucose, and—to a lesser extent—fatty acids, but the
ATP generation rate is slower for the latter, producing reactive oxygen species (ROS) in addition.
Under normoxic conditions, glucose is catabolised to pyruvate, which is then transported to the
mitochondria to form acetyl-CoA by the pyruvate dehydrogenase enzyme complex. Acetyl-CoA
enters the tricarboxylic acid cycle (Szent–Györgyi–Krebs cycle) for further metabolism and produces
CO2 and reduced coenzymes such as NADH, succinate and FADH2. The oxidation of the reduced
coenzymes provides electrons for the respiratory complex I (NADH dehydrogenase) and complex II
(succinate ubiquinone oxidoreductase), respectively. Through sequential redox reactions, electrons
are transferred through these complexes to molecular oxygen, providing energy to pump protons to
complexes I, III and IV, across the inner membrane and into the inner membrane space. This results in
the formation of a proton gradient known as the membrane potential. Hence, the energy stored in
an electrochemical gradient is driven by the reduction of molecular oxygen (O2) to water (H2O). At the
end of the process, within complex V (H+-ATP synthase), the backflow of protons occurs, coupled with
the enzymatic phosphorylation of ADP, and results in the production of ATP. This process is known
as oxidative phosphorylation. Ultimately the redox energy is utilised to generate a proton gradient,
the energy of which is then converted to the production of high-energy macromolecules. Protons
can also flow through uncoupling proteins, dissipating their potential energy into heat (reviewed
by [4,5]). Interestingly, mitochondrial activity can be regarded as a double-edged sword: on the one
hand, most of the O2 consumed by the mitochondria is fully reduced to water within complex IV;
on the other hand, a smaller proportion (1–2%) of O2 is partially reduced to the superoxide anion
(O2−), the overproduction of which constitutes a potential danger. If the function of one or more
respiratory chain complexes is impaired (e.g., due to a mutation in the gene of a protein constituent of
the respiratory complex), the enhanced production of free radicals further worsens the mitochondrial
function. This leads to oxidative damage, and, by opening the mitochondrial permeability transition
pores (mtPTPs), this process induces apoptosis (reviewed by [4]). The elevated level of reactive oxygen
species (ROS) and nitrogen species (RNS) causes oxidative damage to the DNA, as well as covalent
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modification of proteins, lipid peroxidation and the inhibition of mitochondrial enzymes and function,
ultimately triggering carcinogenesis and cell death pathways.
There are two major groups in the antioxidant defence system of the cell, namely enzymes
(superoxide dismutase, catalase, peroxidase, peroxiredoxin and some supporting enzymes), and low
molecular weight antioxidants; and the indirect-acting antioxidants (e.g., chelating agents) and the
direct-acting compounds (e.g., glutathione, NADPH and exogenous agents from dietary sources: ascorbic
acid, lipoic acid, polyphenols and carotenoids) [6,7]. Mitochondria-permeable antioxidants include
edaravone, idebenone, α-lipoic acid, carotenoids, vitamin E and coenzyme Q10 and mitochondria-
targeted antioxidants are MitoQ and astaxanthin.
Mitochondria contain several (2–15 copies) double-stranded, circular genomes that regularly
replicate in postmitotic cells, typically once per month; replication is performed by the nuclear derived
DNA polymerase gamma (PolG) [8]. Individual strands of mtDNA differ in their base composition:
the heavy strand is rich in guanines and encodes the majority of mitochondrial genes, while the light
strand is rich in cytosines and carries genes for one polypeptide and eight tRNAs. Mitochondrial DNA
species are highly redundant, their number ranging from several hundreds to several thousand copies
per cell [9]. Mitochondria contain 16,569 base pairs genomes building 37 genes, 13 being translated
into proteins, 22 tRNAs and two rRNAs. The mtDNA is associated with several proteins, hence they
form complexes known as nucleoids. The majority of the approximately 1500 mitochondrial proteins
are encoded in the nucleus, apart from the 13 proteins that are a of mtDNA. The rate of mutation is
10-fold higher than that for nDNA. Moreover, the mitochondria continuously divide and fuse with
each other, independently of the cell cycle. The cells may therefore contain both normal and potentially
modified mitochondrial genes. The proportion of these can alter during ageing, and clinical symptoms
might appear above a certain threshold (‘threshold effect’). After cell division, the rates of mutant
genomes differ in the individual descendant cells, being highly sensitive to ROS/RNS-mediated injury.
Mitochondrial disorders are maternally inherited or sporadic. mtDNA is considered more vulnerable
to oxidative stress. This is because it consists of only small portions of non-coding sequences; it lacks
introns and protective histons, and is in close proximity to the site of ROS production, having limited
repair systems and deficiencies in the proofreading capacity of PolG during the mtDNA replication
(reviewed by [4]). While mtDNA is coding several proteins—being constituents of four out of the
five mitochondrial respiratory complexes—mutations in the mtDNA might result in the abatement
of mitochondrial function and ultimately lead to mitochondrial disorders [10]. Mitochondria are
supposed to accelerate ageing by ROS overproduction and the accumulation of mtDNA mutations [11].
3. Changes in Mitochondrial Dynamics and Mitophagy in Senescence
3.1. Dynamics
Mitochondria are highly mobile particles, forming dynamic interconnected networks of long
tubules that belong to the cytoskeleton, which is then regulated by mitochondrial dynamics.
The functional and morphological state of this network has a tremendous impact on the bioenergetic
status of the cell.
The morphology and function of mitochondrial networks is regulated by continuous fusion and
fission cycles, which are not only of the utmost importance in maintaining mitochondrial function, but
also constitute a quality control system and regulate cell death pathways. This means that damaged
mitochondria might be restored by the fusion with neighbouring intact mitochondria. In the case
of severe damage via fission, mitochondria are segregated and delivered to lysosomes for digestion
(mitophagy). Through this continuous mixing of the content of the mitochondria, the removal of
damaged ones, and due to the possibility of forming new organelles, it became possible to preserve
a homogenous mitochondrial population and to dilute DNA faults. These complicated actions allow the
cells to exercise quality control upon mitochondrial content and network. Mitochondrial dynamics are
supposed to have important physiological roles in maintaining cell homeostasis [12,13]. Mitochondrial
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dynamics also have a role in safeguarding mitochondria integrity in the light of mtDNA mutations.
Mitochondrial fission plays an essential role in cell survival, by removing dysfunctional mitochondria,
thus alleviating ROS overproduction and oxidative damage of the neurons. During ageing, a decrease
in mitochondrial dynamics has been reported, potentially compromising the function of mitochondria.
The term mitochondrial biogenesis not only encompasses mitochondrial dynamics, but also
regulation of the transcription and translation of both nuclear- and mitochondrial-encoded genes.
Many factors trigger mitochondrial biogenesis, including mitochondrial damage, cell division,
decreased cellular energy, sympathetic stimulation, calorie restriction, exercise, cold stress and certain
hormones (thyroid hormone, erythropoietin, leptin) [14].
Mutations or alterations in mitochondrial dynamics are critical factors associated with several
conditions and disorders; moreover, they are supposed to play a prominent role in cell death during
senescence. An impairment in mitochondrial dynamics has been reported in several cardiovascular
and metabolic conditions (myocardial ischemia–reperfusion injury, type 2 diabetes, hyperglycaemia,
heart failure, obesity), age-related sarcopenia, certain neurological diseases (neuropathies), and several
neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s (PD), Huntington’s
disease (HD), as well as amyotrophic lateral sclerosis (Table 1) reviewed by [15,16]).
Mitochondrial fusion takes place by the activations of the three GTP-ase proteins: mitofusin 1 and 2
(Mfn1 and Mfn2), responsible for the fusion of outer mitochondrial membranes between two organelles;
and optic atrophy protein 1 (OPA1), controlling inner membrane fusion. However, mitochondrial fission
is regulated by the dynamin-related protein 1 (Drp1) and fission protein 1 (Fis1), which are recruited to the
outer mitochondrial membrane where the latter causes a constriction and thereby initiates fission. It should
be added that the mutation of the related genes potentially leads to disorders. For instance, the Mfn2 gene
is responsible for either Charcot–Marie–Tooth disease 2A (CMT2A), a peripheral neuropathy characterised
by muscle weakness and axonal degeneration, or hereditary motor and sensory neuropathy type VI
(HMSN VI), which is clinically similar to CMT with the addition of optic atrophy and visual impairment.
Another example is the mutation of the OPA1 that causes the most common form of optic atrophy, namely
autosomal dominant optic atrophy, clinically characterised by a progressive loss of vision, along with
a degeneration of the optic nerve and retinal ganglion cells. Interestingly, an extensive fragmentation of
the mitochondrial network has been reported in the above mentioned disorders [17].
Table 1. Diseases with abnormal mitochondrial dynamics (based on Ref. [15,16]).
Diseases Mutations Abnormal Mitochondrial Dynamics
Neurodegenerative
disorders
Familial forms of
Parkinson’s diseases
PARK2 and PARK6
(PINK1) genes Abnormal Parkin and PINK1 proteins impair mitophagy
Alzheimer’s diseases increased mitochondrial fission
Huntington’s disease Huntingtin gene mutant huntingtin impair mitochondrial trafficking
Amyotrophic lateral
sclerosis
Superoxide
dismutase 1 gene Drp1-mediated mitochondrial fission
Cardiovascular
diseases
Cardiac hypertrophy
Heart failure excessive fission and/or decreased fusion
Myocardial infarction
Myocardial
ischemia–reperfusion injury excessive fission and/or decreased fusion
Metabolic Diseases
Type 2 diabetes mellitus excessive fission and/or decreased fusion
Glucose intolerance excessive fission and/or decreased fusion
Insulin resistance
Obesity
Others
Charcot-Marie-Tooth
syndrome Mitofusin-2 gene altered axonal mitochondrial transport
Dominant Optic Atrophy OPA1 and OPA3genes mitochondrial fission/fusion defect
Sarcopenia aberrant mitochondrial fission/fusion
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3.2. Mitophagy
Autophagy is defined as a self-elimination process through which cells degrade their own
components, while recycling amino acids and other building parts that can eventually be reused.
Macroautophagy generally refers to a multistep process, during which larger, damaged or unnecessary
cellular elements are removed through sequestration into membrane-engulfed autophagosomes. These
fuse with lysosomes to form autolysosomes, wherein the enveloped content is degraded.
The autophagy of the mitochondria is known as mitophagy. This process regulates the number of
mitochondria according to metabolic demands, and it also serves as a quality control mechanism to
eliminate damaged mitochondria. Mitophagy is preceded by mitochondrial fission, which divides
mitochondria into pieces for engulfment, followed by disposal.
During the mitophagy process, the initiating event is the loss of the mitochondrial membrane
potential of damaged mitochondria (and eventually the opening of mtPTPs), which leads to the
accumulation of the PTEN-induced putative kinase (PINK1) at the outer membrane of the mitochondrion,
which in turn phosphorylates Parkin, Mfn2 and other proteins. Parkin is a cytosolic E3-ubiquitin
ligase that is selectively recruited to damaged mitochondria. Activated Parkin ubiquitinates the outer
mitochondrial membrane proteins. Ubiquitin-tagged mitochondrial proteins, in turn, assist in the
recruitment of autophagosomal membranes to mitochondria, and trigger their fragmentation and
degradation [13]. Defective autophagy has also been associated with a number of disorders, including
metabolic conditions, neurodegenerative disorders, different types of cancer and infectious diseases [18].
According to Sebastian and co-workers, the alteration of mitochondrial fusion and fission proteins could
promote mitochondrial damage and dysfunction, ultimately leading to impaired autophagy/mitophagy.
This results in the accumulation of aberrant mitochondria that might be key features of ageing and
age-related neurodegenerative disorders. A better insight into these mechanism, and the modulation
of mitochondrial dynamics might be promising therapeutic targets in influencing specific age-related
disorders [16].
4. Peroxysome Proliferator-Activated Receptor-Gamma (PPARγ) Coactivator 1-alpha (PGC-1α)
PGC-1α is a miraculous, nuclear-encoded coactivator enzyme of a wide range of transcriptional
factors (such as nuclear respiratory factor 1 and 2 /NRF-1, -2/, PPARs, oestrogen-related receptors
/ERRs/, and myocyte-specific enhancer factor 2C/(MEF2C/), therefore it is considered to be the main
organiser of cell energy metabolism. One of its main targets is PPARγ, presumably being a major
signalling pathway involved in neuroinflammation [19]. This process might coactivate genes, which
encode proteins for transcription and replication of mtDNA, thus promoting mitochondrial biogenesis.
It provides a direct link between external physiological stimuli and the regulation of mitochondrial
biogenesis, and it is a major factor that regulates muscle fibre type determination. It plays a role
in controlling blood pressure, regulating cellular cholesterol homoeostasis, and the development of
obesity (“Entrez Gene: PPARGC1A peroxisome proliferator-activated receptor gamma, coactivator
1 alpha”). It may be activated by a large number of factors, including endurance physical exercise,
cold exposure and starvation, involving energy deprivation and stress evoked by ROS and RNS [5].
Impaired mitochondrial biogenesis and associated mitochondrial dysfunction as well as neurogenic
inflammation are reported to have significant roles in the pathogenesis of neurodegenerative disorders.
An approach to promote PGC-1α activity in order to boost mitochondrial energetics, or PPARγ
agonists in order to alleviate neurogenic inflammation, holds promise for the future treatment of these
devastating disorders.
5. The Role of Reactive Oxygen Species (ROS)
The loss of electrons is referred to as oxidation. The adducts generated during this process are
termed free radicals (oxidising agents). A characteristic of these radicals is the ability to transmit
their electrons to other molecules, thus causing oxidative damage. Cellular mediators of oxidative
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stress are O2-radicals, generated by the electron transport chain (ETC) by electron transport itself.
These are quickly converted to H2O2, a principal actor in oxidative stress. Moreover, their derivatives,
the hydroxyl radicals are extremely reactive in causing oxidative damage to DNA, especially strand
breaks, abasic sites and oxidative DNA adducts [20]. As mentioned earlier, the nervous system is
particularly vulnerable to the deleterious effects of ROS for several reasons. Their high concentration
of polyunsaturated fatty acids may be targets of lipid peroxidation; they consume a high amount of
oxygen to produce energy, and their antioxidant system is relatively deficient [21]. It is well known
that adult neurons are in a constant post-mitotic state, hardly replicating themselves during life. Hence,
the number of damaged neurons grows throughout the lifespan, with neurons being more sensitive to
the accumulation of oxidative damage, as compared to mitotically active cells, and also more prone to
accumulating defective mitochondria [22]. The abnormal accumulation of toxic free radicals causes
oxidative and nitrosative damage to proteins, lipids and DNA molecules [23]. Oxidative stress acts
through several pathways: by causing bioenergetic failure, depletion of antioxidant defences, damage
to proteins and other macromolecules, microtubular disruption, ion channel activation, demyelination,
neuroinflammation, mitophagy and apoptotic cell death (reviewed by [24]). Overactivation of these
pathways leads to neurodegeneration, the slow death of cells observed in senescence and in several
neurodegenerative disorders. Nevertheless, it should be mentioned that ROS also have important
physiological functions in the cell, such as homeostasis, apoptosis, necrosis, synaptic plasticity,
antimicrobial defence reaction, inflammation, as well as learning and memory [25].
6. Ageing
Ageing is characterised by a progressive deterioration in physiological functions and the integrity
of cells and tissues, leading to an increased vulnerability to certain age-related diseases like cancer,
diabetes, atherosclerosis, heart failure, hypertension, cataracts, neurodegenerative diseases, and also
death [26]. Ageing is thought to have multiple causes, involving genetic, epigenetic, environmental and
lifestyle factors. The combination of these leads to an aged phenotype, heralded by slower movement
and thinking, muscle weakness, grey hair, facial wrinkles and skin atrophy, among others [27]. Human
ageing commences as early as the third decade. As neurons consume a lot of energy in order to maintain
their optimal functioning, it is evident that the brain is highly dependent on a continuous supply of ATP.
The proper functioning of several pathways assures the optimal maintenance of mitochondrial integrity,
namely faithful DNA replication, efficient DNA repair, abundant ROS elimination, mitochondrial
morphology regulation through fission and fusion, as well as mitophagy.
As energy production is strongly associated with mitochondria, any disturbance in mitochondrial
function could be the starting point for several diseases including neurodegenerative disorders.
Mutations in nuclear or mitochondrial DNA, dysfunction of mitochondrial dynamics and mitophagy,
along with decreased ATP production and oxidative damage, can create a vicious circle that aids
mitochondrial damage and causes a deficiency in their ATP-generating capacity [11,28].
According to Grimm and Eckert, brain ageing is characterised by increased oxidative stress and
a decrease in antioxidant defences, ultimately leading to protein and DNA oxidation, lipid peroxidation,
and a further deficit in oxidative phosphorylation. These events create a vicious circle whereby
enhanced ROS production might trigger oxidative stress. If this process is in balance, it leads to normal
ageing. However, when enhanced ROS production prevails, above a certain threshold it can lead to
mitochondrial dysfunction and apoptosis [29]. Several reports suggest that mitochondrial damage per
se cannot alone be responsible for ageing, noting that genomic instability and the accumulation of DNA
mutations also constitute important factors [30,31]. Defects in the mtDNA replication mechanism and
a failure in the repair of mtDNA might result in the accumulation of mutations, leading to mitochondrial
dysfunction like decreased ETC enzyme activity and impaired cellular respiration [32]. In addition,
aggregated, misfolded proteins also contribute to the pathomechanism of several neurodegenerative
disorders and the process of ageing. These proteins are hyperphosphorylated tau and amyloid plaques
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in AD, alpha-synuclein in PD, mutated huntingtin in HD, and mutant SOD1 in ALS, which add to
mitochondrial dysfunction via the inhibition of the proteasome system.
7. The Role of Free Radicals in Ageing
The free radical theory of ageing was put forward by Harman in 1954 [33,34]. According to
this theory, ageing is driven by the growing expression of free radical damage with time by both
endogenous and exogenous sources, and incompletely repaired by processes dependent on ATP [35].
The gradual loss of efficiency of mitochondrial oxidative energy metabolism during life may be
an important contributor to both the ageing process and several neurodegenerative disorders.
The accumulation of mitochondrial gene mutations might well play a role in this process [36,37].
Several theories have evolved since then with the majority agreeing that cumulative damage to
mitochondria caused by ROS is a primary driving force of ageing and a major determinant of
the individual lifespan. Mutations in mtDNA caused by ROS alter the expression of oxidative
phosphorylation complexes (mostly complex I and IV, encoded by mtDNA), leading to compromised
energy production (reviewed by [38]). Based on animal experiments, S. Hekimi proposed the gradual
ROS response hypothesis of ageing. ROS might also stimulate beneficial responses to cellular stressors
produced by ageing. As ageing progresses, the level of ROS generation becomes maladaptive and ROS
dependent damage contributes to the stimulation of the ROS-dependent stress responses, leading to
the further elevation in ROS generation and ROS damage. When a certain threshold of ROS is reached,
this starts to add additional damage to the tissue potentiating tissue dysfunction and ageing [39].
Taken together, it may be concluded that ageing is characterised by the decrease of mitochondrial
function and ATP production, the generation of exaggerated ROS causing oxidative stress, the abatement
of mitochondrial dynamics, biogenesis, and also abnormalities in mitochondrial quality control and the
accumulation of apoptotic cell death [40].
8. Alterations in the Genome of Cells in Senescence
A failure to repair DNA structural alterations can produce a mutation. There are several agents
that are harmful to DNA molecules, such as ROS, ionising radiation, ultraviolet rays (UV-C and
UV-B), and chemical agents (plant and microbial products, e.g., aflatoxin; chemotherapeutics, cigarette
smoke). These factors alter DNA through a variety of chemical actions, involving oxidation, alkylation,
hydrolysis and formation of adducts, as well as the mismatch of nucleotide bases or DNA strand
breaks (single strand breaks /SSBs/ and double strand breaks /DSBs/). The consequent types of DNA
damage types include single-nucleotide base alterations, nucleotide base pair alterations, chain breaks
and cross linkage.
Nature has evolved using a broad repertoire for the repair of DNA faults involving direct damage
reversal or the excision of the DNA damage. The former is a mechanism for restoring the DNA to
its normal state, whereas during excision repair (where SSBs occurs), single or several nucleotide
modifications are corrected. Strand discontinuity serves as a signal to direct mismatch repair (MMR) to
the discontinuous strand of a mismatched duplex. Postreplicative MMR is performed by the long-patch
MMR mechanism, during which multiple proteins are involved, and a relatively long tract of the
oligonucleotide is excised as part of the repair reaction. This is followed by DNA polymerase replacing
the missing section with correct nucleotides, and an enzyme called DNA ligase that seals the gap. DNA
DSBs are viewed as potentially lethal lesions. DNA non-homologous end-joining (NHEJ) is the major
DSB rejoining process and occurs in all cell cycle stages. The highly toxic interstrand DNA cross links
are very difficult to repair, as both strands are damaged, and hence neither of the strands is capable of
acting as a template for the other one (reviewed by [10]). If the cell cannot cope with the large amount
of DNA damage, there are three possible states that it can evoke: (1) senescence—an irreversible state
of dormancy; (2) apoptosis; or (3) unregulated cell division leading to cancer formation. Besides DNA
repair, there are other possibilities for eliminating damaged mitochondria (and their DNAs), namely
poly-ADP-ribose polymerase 1 (PARP-1) and mitophagy. In fact, increased activation of PARP-1
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with age has been reported as a response to DNA damage, which in turn might be involved in the
increased ATP consumption in senescence [30]. In human cells, DNA damage may be caused by both
normal and altered metabolic activities (ROS), environmental factors (such as radiation, including
ultraviolet 200–400 nm, X-rays, gamma rays), chemical agents (certain plant toxins, human made
mutagenic chemicals), hydrolysis/thermal disruption, as well as viruses, resulting in about 10,000 to
1 million individual molecular lesions per cell per day. In senescence, many cells no longer divide,
which is considered a useful strategy for protecting the organism against cancer. In senescence,
genome alterations—even if present in higher frequency—are not transmitted to the offspring [41].
Although sophisticated repair machinery ensures deletion or correction of DNA faults in humans, some
of these alterations could remain unrepaired. Irreparable DNA damage, including DSBs and DNA
crosslinkages, can eventually lead to malignant tumours, or even cell death. Senescence is characterised
by defective repair capacity and the abundance of DNA damage. Several genes are thought to influence
life span, the majority of which are involved in the DNA repair process [9]. Depending on the type of
lesion (i.e., a chemical modification or hydrolysis of a base; or an incorrectly incorporated base during
replication), several repair mechanisms have been developed by the organism.
These are the following:
1. Proofreading repair: DNA polymerases also possess a 3′–5′ exonuclease activity, providing for
the immediate repair of incorrectly built bases and the subsequent correction of synthesis with the
proper complementary base.
2. Direct reversal repair: This eliminates some DNA modifications without the use of
excision, resynthesis or ligation. Therefore, since direct reversal repair does not require breaking
of the phosphodiester backbone, this constitutes an error-free repair mechanism and preserves
genetic information.
3. Single-strand damage repair: If only one of the two strands forming the double helix is
defective, the unaffected strand can serve as a template for repair. Single strand breaks (SSBs) are
discontinuities of one strand of the helix, mostly caused by ROS, or occur during the process of another
type of repair, which is termed base excision repair (BER). The main steps of reversal are: recognition
of the fault, strand scission, gap tailoring, DNA synthesis and ligation.
4. Excision repairs: These repair systems remove the faulty synthesised base, or the short DNA
sequence region containing the misincorporated base, and subsequently re-synthesise the correct DNA
backbone, according to the intact DNA strand template.
4a. Base excision repair (BER) (Figure 1): Both the short-patch BER and the long-patch BER are
the predominant DNA repair pathways in mitochondria, used especially to reverse ROS-induced single
base damage, as well as repair the majority of DNA lesions produced during episodes of inflammation,
exposures to ionising radiation and a variety of chemical carcinogens [42]. After recognition of
the defected nucleotide by a glycosylase (such as OGG1), the same enzyme removes it by creating
an apurinic or apyrimidinic site (AP). Then the enzyme apurinic/apyrimidinic endonuclease 1 (APE1)
nicks the damaged DNA backbone and leaves a single stranded DNA gap. Next, the gap is filled
by a DNA polymerase (DNA pol-β) either by a single base (short-patch) or by several bases that
synthesise a small oligonucleotide (long-patch), the superfluous part of which is then removed by
a flap-endonuclease (e.g., FEN1). A ligase, together with the scaffolding protein XRCC1, then seals the
DNA backbone. Lastly, the correct restoration of the DNA continuity takes place, with this pathway
resulting in an “error-free” restitution [30]. BER has been reported to play a role in ageing, cancer
and neurodegeneration.
Along with the exaggerated oxidative damage to mitochondrial DNA supposed to take
place during senescence, an inefficient mitochondrial BER mechanism in late life can also add to
mitochondrial DNA damage [43]. Based on several in vitro studies, in the absence of BER enzymes,
cells accumulate mutations and are hypersensitive to a variety of damaging agents. It has also
been reported that lesions repaired by the BER pathway can initiate carcinogenesis, suggesting that
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individuals who have compromised BER have a greater risk of developing cancer. Hence, modulation
of the levels of BER proteins could provide a gene therapy approach that targets cancer cells [42].Molecules 2018, 23, 191 9 of 28 
 
 
Figure 1. Base excision repair [10,30,44]. 
4b. Nucleotide excision repair (NER) (Figure 2) performs the excision of the DNA lesions, not 
just in one base. In some special cases, it fails to recognise the damage and instead, BER is activated 
in order to make the fault overt for other repair mechanisms. NER is believed not to occur within the 
mitochondria. NER is the main pathway responsible for the removal of bulky, helix distorting 
damage caused by UV irradiation, environmental mutagens, and some anticancer agents. NER 
involves the action of over 30 proteins functioning in a sequential series of reactions that can be 
summarised as follows: damage recognition, isolation, localised strand unwinding, the assembly of 
a repair complex, excision of the damage-containing strand 3′ and 5′ to the lesion, synthesis of a 
sequence-appropriate replacement strand, and finally, ligation to restore continuity of genomic 
DNA [45,46]. According to the mechanism of damage detection, there are two pathways, namely the 
transcription coupled pathway (TC-NER), and the global genomic NER (GG-NER) mechanism. 
While these may differ at first, during the subsequent steps they converge to one common repair 
pathway. In TC-NER, the lesion blocks RNA polymerase action—which actually initiates the 
pathway—whereas GG-NER is activated by damage-sensing proteins [47]. 
Figure 1. Base excision repair [10,30,44].
4b. Nucleotide excision repair (NER) (Figure 2) performs the excision of the DNA lesions, not
just in one base. In some special cases, it fails to recognise the damage and instead, BER is activated in
order to make the fault overt for other repair mechanisms. NER is believed not to occur within the
mitochondria. NER is the main pathway responsible for the removal of bulky, helix distorting damage
caused by UV irradiation, environmental mutagens, and some anticancer agents. NER involves the
action of over 30 proteins functioning in a sequential series of reactions that can be summarised as
follows: damage recognition, isolation, localised strand unwinding, the assembly of a repair complex,
excision of the damage-containing strand 3′ and 5′ to the lesion, synthesis of a sequence-appropriate
replacement strand, and finally, ligation to restore continuity of genomic DNA [45,46]. According
to the mechanism of damage detection, there are two pathways, namely the transcription coupled
pathway (TC-NER), and the global genomic NER (GG-NER) mechanism. While these may differ at
first, during the subsequent steps they converge to one common repair pathway. In TC-NER, the lesion
blocks RNA polymerase action—which actually initiates the pathway—whereas GG-NER is activated
by damage-sensing proteins [47].
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4c. Mismatch repair (MMR) (Figure 3) is performed if a non-corresponding base is built into
the ribose backbone during replication. This nucleotide then remains unrecognised by the DNA
polymerase during replication. Detection of the mispaired base by the Msh2/Msh6 or Msh2/Msh3
complex leads to the recruitment of the Mlh1 and the endonuclease Pms, followed by resynthesis
of the DNA sequence by a DNA polymerase. Lastly, the newly synthesised DNA strand is cleaved
by an endonuclease close to the damaged site. Malfunction of the MMR mechanism also enhances
the risk of cancer. Defects in mismatch repair lead to a significantly increased risk of non-polyposis
colorectal cancer.
Molecules 2018, 23, 191 11 of 28 
 
4c. Mismatch repair (MMR) (Figure 3) is performed if a non-corresponding base is built into 
the ribose backbone during replication. This nucleotide then remains unrecognised by the DNA 
polymerase during replication. Detection of the mispaired base by the Msh2/Msh6 or Msh2/Msh3 
complex leads to the recruitment of the Mlh1 and the endonuclease Pms, followed by resynthesis of 
the DNA sequence by a DNA polymerase. Lastly, the newly synthesised DNA strand is cleaved by 
an endonuclease close to the damaged site. Malfunction of the MMR mechanism also enhances the 
risk of cancer. Defects in mismatch repair lead to a significantly increased risk of non-polyposis 
colorectal cancer. 
 
Figure 3. Mismatch repair [10,30,44]. 
5. Double strand break repair (DSBR) is responsible for the correction of breaks in both DNA 
strands. DSBs may be generated as a consequence of normal cell metabolism, or as a consequence of 
ionising radiation or chemotherapeutic drugs. Furthermore, DSBs are intermediates in several 
programmed recombination processes. These mechanisms are available for the correction of the 
most severe DNA lesions, and, if the former correction processes (e.g., direct reversal and excision 
repairs) have failed. DSBR mechanisms are complex and sophisticated. This is due to the fact that, 
unlike the previous mechanisms, there is no intact strand available to serve as a template. After DSB 
has occurred, end fragments will move away in a few milliseconds. In order to correctly connect the 
break ends again, a sophisticated mechanism has to be activated to directly ligate them; or, in 
another scenario, a homologous DNA sequence has to be found by the cell, which then assists in 
Figure 3. Mismatch repair [10,30,44].
5. Double str nd br ak repair (DSBR) is responsible for the correction of breaks in both DNA
strand . DSBs may be gen rated as a consequence of normal cell metabolism, or as a con quence
of ionising ra iation or chemotherap utic drugs. Furthermore, DSBs are in ermediates in several
programmed recombination processes. These mechanisms ar available fo the cor ectio of the most
severe DNA lesions, and, if the former correction processes (e.g., direct reversal and excision repairs)
have failed. DSBR mechanisms are complex and sophisticated. This is due to the fact that, unlike the
previous mechanisms, there is no intact strand available to serve as a template. After DSB has occurred,
end fragments will move away in a few milliseconds. In order to correctly connect the break ends
again, a sophisticated mechanism has to be activated to directly ligate them; or, in another scenario,
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a homologous DNA sequence has to be found by the cell, which then assists in substituting the faulty
sequence and repairs the break. This kind of damage is especially hazardous to the cell, since any
failure to repair a chromosomal DSB can cause genome rearrangements, or even cell death. What is
more, inaccurate repair can potentially lead to mutagenesis.
There are two major sub-pathways for the repair of DSBs. These are:
5a. The homologous recombination (HR) (Figure 4) is a type of genetic recombination in which
nucleotide sequences are exchanged between two similar or identical molecules of DNA, i.e., HR
uses a sister chromatid (formed during the G2 phase of cell cycle) or an identical sequence of the
homologous chromosome as a repair template. The enzymatic mechanism responsible for this repair
process is nearly identical to the mechanism that carries out chromosomal crossover during meiosis.
It should be mentioned that the term HR is also accurate for situations where a change of a DNA
section with another homologous chromosome sequence takes place. Moreover, HR can occur between
the homologous DNA sequences of a virus, bacterium or a eukaryotic cell.
The role of HR during the reparation of DSBs, during and shortly after DNA replication, namely in
the S and G2 phases of the cell cycle, is also predominant. If a double-strand break occurs, the recognition
proteins first relax the DNA strand, followed by the resection of a section of DNA around the 5′ ends
(by MRN complex, Exo1 and other nucleases). MRX complex recruits the Sae2 protein in order to
hold the strand in a linear state. Parallel to this process, the search for a homologous sequence begins.
If a similar/identical (sister chromatid) sequence is successfully found, the double-strand DNA is
“unzipped” and unwound in order to allow the original, broken and overhanging 3′ end to be placed
opposite the intact template helix of the newly involved DNA. The term “invasion” refers to the process
during which the sister chromatid is used to form a D-loop structure. Behind the recombination point,
the four DNA strands form a peculiar shape, similar to a rectangle railway junction, which is called
the ‘Holliday junction’. After finding the right position, resynthesis and substitution of the DNA takes
place. After the strand invasion, another sequence of events follows one of the two pathways: the DSBR
pathway or the SDSA (synthesis-dependent strand annealing) pathway. Dysfunction of the HR process
is strongly associated with increased susceptibility to several types of cancer, which helps explain why
the proteins that facilitate HR are topics of active research. HR is also used in gene targeting, a technique
connected with the introduction of genetic changes into the target organism.
5b. Non-homologous end joining (NHEJ) (Figure 5) refers to the break ends being directly
ligated with no need for a homologous template. It is predominant in the G1 phase of the cell
cycle, with the cell growing, but not yet ready to divide. NHEJ involves the direct ligation of DNA
ends with little or no homology, and it is generally considered to be an “error-prone” process, since
nucleotides can be lost or gained at the ends, prior to ligation. Furthermore, in cells with multiple
DSBs on different chromosomes, end joining can result in chromosome translocations [49]. NHEJ
takes place when a special DNA ligase, added to a cofactor, is able to find the ends that fit each
other. Repair will be accurate if one of the two single-stranded tails at the break (also termed
“overhangs”) is longer compared with the other end of the broken DNA. This is due to the possibility
of the broken end containing short homologous sequences, (i.e., microhomologies) being longer
(microhomology-mediated end joining [MMEJ]. If these “overhangs” are perfectly compatible, repair is
usually accurate. However, if the broken ends are of similar length, the chance of finding corresponding
DNA sequences is lower, and the risk of forming chromosome aberration increases. During NHEJ,
mutations can also occur. Loss of damaged nucleotides at the break site can lead to deletions, and the
joining of non-matching termini results in insertions or translocations.
6. Repair of interstrand crosslinks. The crosslinking of DNA is defined as the process of
agents linking two different points of the DNA sequence. This either occurs within the same strand
(intrastrand crosslink), or in opposite strands of the DNA (interstrand crosslink). The latter are highly
toxic lesions that are extremely difficult to repair, since both strands are affected, hence one strand
cannot act as a template for the other. The repair of crosslinks occurs through the HR process. DNA
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replication is blocked by crosslinks, causing replication arrest and cell death if the crosslink is not
repaired. Here, the RAD51 family plays a crucial role in the repair mechanism.
In summary, preserving mtDNA integrity is a prerequisite for maintaining the optimal function
of mitochondria. Good DNA repair machinery is of vital importance in achieving this goal, and any
disturbance in safeguarding cell mechanisms might make it susceptible to age-related disorders and
assist ageing processes including progeria syndromes.
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9. PARP
The PARP family consists of 17 members. PARP-1 accounts for more than 90% of cellular PARP
activity. It is mostly found in the nucleus and to a lesser extent in the cytosol, while the question
of its presence in mitochondria is still being debated. These proteins play a role in a number of
cellular functions including DNA repair, the regulatio of i flammation and metabolic processes,
ageing, as well as programmed cell dea h. Cell homeostasis is nfluenced via lipid, glucose and
hormone metabolism, circadian rhythm, food i take, and also plays a signific nt role in mitochondrial
homeostasis [51]. Nevertheless, the best-know function of PARP is DNA repair, i. ., assisting in the
repair of single-strand DNA nicks, and i itiating BER. Besides this, some recent studies implicate the
role of PARP-1 in facilitating HR and NHEJ. The hallmark action of PARP-1 is the poly ADP-ribosylation
(PARylation) of PARP and other DNA-binding proteins. PARP serves as a molecular sensor of DNA
breaks evoked by X-rays, alkylating agents and ROS. In the event of SSBs, the DNA binding domain
of PARP-1 (composed of two zinc finger motifs) binds to the damaged sites, where it undergoes
homodimerisation, a reversible post-translational protein modification, through the local synthesis of
a poly (ADP-ribose) (PAR) chain from nicotine adenine dinucleotid (NAD+). The cleavage of NAD+
results in nicotinamide and ADP-ribose, the latter being used for the synthesis of long branching PAR
polymers, which covalently bind to PARP itself, as well as other DNA binding proteins (histones, DNA
repair enzymes and transcription factors). PARylation results in highly negatively charged nuclear
proteins, which, in turn lead to the repair of the damaged DNA through the BER pathway. This acts as
a signal for the other DNA-repairing enzymes, i.e., DNA ligase III (LigIII), DNA polymerase beta (polβ),
and X-ray cross-complementing gene 1 (XRCC1). After BER occurs, PAR chains are degraded via poly
(ADP-ribose) glycohydrolase (PARG). PARP itself is inactivated by cleavage involving caspase-3 and
caspase-7. The action of PARP-1 is two-fold, as failure to repair SSBs can result in DSBs. However,
the a tivation of PARP-1 caused by mild genotoxic stimuli ma f cilitate DNA re air and cell survival.
In contrast, if extensive DNA damage occurs, PARP-1 becomes overactivated, and, along its enzymatic
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pathway, rapidly depletes the intracellular NAD+ and ATP pools. This results in a profound energy
loss of the cell. In addition, the rate of glycolysis and mitochondrial respiration slows down, ultimately
leading to cell dysfunction, or even cell death. The latter is a result of the incapacitation of the apoptotic
machinery, switching the mode of cell death from apoptosis to necrosis [52]. Of interest, PARP-1
over-activation has been shown to be involved in the pathogenesis of several diseases. Consequently,
pharmacological inhibition or genetic ablation of PARP-1 was reported to provide protection from
tissue injury in various oxidative stress-related disease models. These beneficial effects are attributed to
the inhibition of the PARP-1 over-activation, which mediates suicidal pathways [53]. PARP-1 inhibitors
are used to increase the activity of DNA-binding anticancer agents. Moreover, PARP-1 inhibitors may
be of help in restoring cellular functions in a number of disorders and pathophysiological states [52].
10. Kynurenines in Ageing
Tryptophan (TRP) is an aromatic essential amino acid that plays an important role in the metabolic
processes of the human body. A small fraction of dietary TRP is used for protein synthesis; a very
small proportion (1%) leads to the formation of serotonin, and, subsequently, a pineal hormone called
melatonin. In the intestinal system, indole and oxindole are produced by resident bacteria.
The main alternative route of TRP metabolism is the kynurenine (KYN) pathway, with nicotinic
acid and its derivatives, the two ubiquitous coenzymes, NAD+ and NADP being the primary end
products (Figure 6). Both of the latter participate in the basic cellular processes, including redox
reactions essential for mitochondrial function and energy production [54–56]. These molecules are
formed from quinolinic acid (QUIN), an intermediate end route that represents, together with KYN
and KYNA, the hallmarks of this pathway. However, there are also several side branches in this
catabolic process, starting from the central compound, kynurenine (KYN) and resulting in kynurenic
acid (KYNA), xanturenic acid (XA) and picolinic acid (PA). It should also be mentioned that TRP
indirectly takes part in glucose and lipid metabolism as well.
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Figure 6. Metabolism of TRP via the KYN pathway. Abbreviations: L-TRP: L-triptophan; L-KYN:
L-kynurenine; 3-OH-KYN: 3-hydroxy-L-kynurenine; 3-OH-AA: 3-hydroxyanthranilic acid; QUIN:
quinolinic acid; NMN: nicotine adenine mononucleotide; NAD+: nicotinamide-adenine dinucleotide;
PA: picolinic acid; AA: anthranilic acid; XA: xanthurenic acid, IDO: indolamine-2,3-dioxygenases, TDO:
triptophan-2,3-dioxygenase, KAT: kynurenine aminotransferase, KMO: kynurenine-3-monooxigenase,
3-OH-AAO: 3-hydroxyanthranilic acid oxygenase, QPRT: quinolinic acid phosphoribosyl transferase.
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11. Kynurenine (KYN) Pathway
In the first metabolic step, TRP-2,3-dioxygenase (TDO) or indolamine-2,3-dioxygenases (IDO)
catalyse the reaction to produce N-formyl-kynurenine. IDO is expressed in various cell types
throughout the body including fibroblasts, macrophages, microglia, monocytes, dendritic cells, as
well as neurons and astrocytes, while TDO is expressed mostly in the liver. IDO can be induced by
several inflammatory substances, including lipopolysaccharides (LPS), interferon-α (IFN-α), IFNβ,
IFNγ and tumour necrosis factor-α (TNF-α), transforming growth factor-β (TGFβ), interleukin-1 and 2
(IL1 and 2), as well as amyloid peptides, while it can be inhibited by elevated levels of TRP [57].
IDO activity has several contradictory effects on immune responses. An overexpression of IDO is
connected with human cancer development, IFN-α-induced depression and irritable bowel syndrome
development [58]. However, expression of TDO can be amplified by corticosteroids, oestrogens and by
TRP itself.
N-formyl-KYN is then further metabolised to L-KYN in a reaction catalysed by formamidase.
This central component is a branch point in the pathway with different fates. Hydroxilation by
kynurenine-3-monooxygenase (KMO) gives rise to 3-hydroxykynurenine (3-OH-KYN), kynureninase
(KYNU) produces anthranilic acid (AA), while kynurenine aminotransferases (I, II, III) (KATs)
desaminate KYN to KYNA. The latter metabolic branch is minor under normal conditions, but it
is enhanced under TRP or KYN loading. KMO is located in the outer mitochondrial membrane. Along
the main catabolic pathway, 3-hydroxyanthranilic acid (3-OH-AA) then 2-amino-3-carboxymuconoate
semialdehyde are produced. The latter undergoes non-enzymatically to form QUIN or is decarboxylated
to produce picolinic acid (PA). QUIN is further metabolised by quinolinic acid phosphoribosyl
transferase (QPRT) in several additional biochemical reactions to niacin and subsequently to NAD+,
the end product. Under specific conditions, PA is formed from QUIN. NAD+ is a coenzyme that
participates in many cellular processes and can be reversibly converted to NADH by the addition of
two electrons and one proton to the nicotinamide ring [33]. The production of QUIN occurs at a much
faster rate within the brain than the conversion to NAD+. Theoretically, enhanced activity of QPRT may
result in lower levels of QUIN (because it is further metabolised to NAD+), which may be advantageous
in neurodegenerative disorders; but in malignant glioma cells, elevated levels of this enzyme may result
in a poorer prognosis through its cytoprotective effect (lower levels of ROS by QUIN) [59]. However,
IDO inhibition reduces NAD+ synthesis and therefore promotes cell death.
While KYNA is produced mainly in astrocytes, QUIN degradation occurs in microglial cells in
the central nervous system. 60 mg of TRP can make 1 mg of niacin. As KYNU (and KATs) necessitate
pyridoxine (vitamin B6) for their functioning, in the case of vitamin B6 deficiency, 3-OH-KYN
accumulates in the blood—which is converted to XA instead of niacin that is excreted in the urine in
high concentrations. Not enough niacin for the organism will be available and this leads to pellagra
(vitamin B6 deficiency), the symptoms of which include dermatitis (inflamed, rough and photosensitive
skin), diarrhoea (because of lesions of the gut mucosa), dementia, and sores in the mouth. Today,
the full clinical picture is realised only in India and in certain southern African countries.
The gastrointestinal tract plays a key role in TRP metabolism. The majority of serotonin is synthesised
in the upper part of it. Resident microbiota have the enzymatic machinery to break down TRP to KYNA
and to indole compounds. These substances can modulate local inflammatory conditions through specific
receptors. These compounds possess ROS scavenging, neuroprotective and anti-inflammatory effects.
They have roles in the maintenance of mucosal homeostasis and barrier function [60].
Recently, attention has turned to the KYN pathway because several intermediates have neuro-
and immunoactive properties, and hence are capable of modulating the activity of certain brain cells
and inflammatory responses.
12. KYNA
Our knowledge about KYNA has broadened tremendously in the past few decades. The first
discovery was made by Kessler and co-workers, who found that this intermediate blocked the glycine
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(Gly)-binding site of the NMDA receptor in low micromolar concentrations (IC50 10–30 µM) [61,62].
A blockade of the glutamate (Glu)-binding site of the NMDA receptor complex requires concentrations
10–20-times higher than those for the Gly site, whereas KYNA exhibits a weak antagonistic effect
on the 2-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and kainate receptors (IC50
300 µM at both receptors) [63]. Interestingly, KYNA also exerts a positive modulatory action at the
binding site of the AMPA receptor [64]. It is also a non-competitive inhibitor at the α7-nicotinic
acetylcholine receptors that are mostly located on pre-synaptic terminals [65]. It appears to be
the primary target of endogenous KYNA in the brain. In high concentrations (100–300 µM) it has
a potential antioxidant property, although such high local concentrations (above 100 µM) can rarely be
achieved in physiological or pathological conditions [66]. KYNA plays an important role in modulating
neural plasticity and cognition. It is mostly synthesised in glial cells. Extracellular concentrations
of KYNA in mammalian brains are in the low nM range, while its affinity for the glycine site of the
NMDA receptor complex is approximately 10–30 µM. Various electrophysiological and behavioural
experiments have demonstrated that a mild increase in brain KYNA concentrations can reduce
excitatory transmission in the brain [67]. The accumulation of rat brain KYNA content during the
ageing process has been reported [68]. There are several neurodegenerative diseases such as HD, AD,
amyotrophic lateral sclerosis, migraines and epilepsy whose pathogenesis is supposed to involve
reduced brain KYNA levels [69], while higher levels of this compound have been found in the brains
of schizophrenic patients. The elevation of KYNA may provide neuroprotection in several of these
disorders [70]. The inhibition of KMO (KYN-metabolising enzyme) by chronic oral administration
of JM6, a small-molecule prodrug was able to increase KYNA levels and decrease extracellular
glutamate levels in a rat brain. In a transgenic mouse model of AD and HD, JM6 ameliorated
neurodegeneration, which confirms a link among TRP metabolism, glutamate neurotransmission and
neurodegeneration [71]. Recently, a new avenue relating KYN pathway metabolites, including KYNA,
has been revealed, namely their functions in the regulation of the innate response and the adaptive
immune response. Furthermore, two new receptors have been discovered at which KYNA exerts
agonistic actions, i.e., GPR35 (IC50 0.1–30 µM), an orphan G protein-coupled receptor, and transcription
factor aryl hydrocarbon receptor (AhR) through which KYNA can ameliorate immune activation [72,73].
KYN is also a ligand for the latter receptor. Elevated KYNA, IgG and beta-2-microglobulin levels in the
cerebrospinal fluid with ageing has been reported suggesting an age-dependent increase of kynurenine
metabolism in the brain and an activation of the immune system during ageing. Increased KYNA
metabolism may be involved in the hypofunction of the glutamatergic and/or nicotinic cholinergic
neurotransmission in the ageing brain partly underlying age-associated cognitive decline [74].
GPR35 receptors are expressed in immune cells, predominantly in circulating monocytes and
in gastrointestinal tissues. Their interaction with KYNA has been shown to promote monocyte
extravasation, reduce inflammatory response to LPS and regulate cytokine release [75]. What is more,
it may reduce glutamate release from glial cells [67].
AhR is a ligand-activated transcription factor that is involved in the regulation of the xenobiotic
response to foreign substances including 2,3,7,8-tetrachlorodibenzo-p-dioxin and dioxine-like
compounds. Upon ligand binding to certain chemicals, AhR translocates into the nucleus and changes
gene transcription by inducing certain xenobiotic-metabolising enzymes, called “the AhR battery”
including cytochrome P450. However, recent evidence has shown that the AhR also has several diverse
effects aside from xenobiotic metabolism, including the regulation of immune and inflammatory
signalling; and it has a role in normal development, the maintenance of homeostasis of several organs
and in tumour growth [76].
Aerobic exercise was reported to induce KAT through PGC-1α1 in skeletal muscles with an
enhanced production of KYNA in the periphery that led to an alleviation of peripheral and brain KYN
levels. This can reduce stress-induced depressive symptoms [60], perhaps by the reduction of KYN
in the brain. Modulating PGC-1α1-PPAR activation in skeletal muscles could be a new therapeutic
approach to regulate TRP-KYN metabolism.
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13. 3-OH-KYN and 3-OH-AA
3-OH-KYN and 3-OH-AA also have neurotoxic properties as they can induce ROS generation and
oxidative stress [77]; moreover, they can promote apoptotic cell death and augment QUIN-induced
excitotoxicity [78]. QUIN and 3-OH-AA have an additional neuromodulatory effect by suppressing
T-cell proliferation [79]. PA has been shown to have a neuroprotective effect and decreased
QUIN-producing neuroblastoma cell growth (in micromolar concentrations) [80].
14. QUIN
QUIN has an excitatory effect in the nervous system. It is a weak, though selective, competitive
agonist at the N-methyl-D-aspartate (NMDA) receptor subgroup containing the NR2A and NR2B
subunits with low receptor affinity (ED50 100 µM) [81,82]. Elevated levels of QUIN can cause excitotoxic
cell death. It is also toxic to oligodendrocytes. The hippocampus and striatum are the most sensitive
brain areas toward QUIN neurotoxicity [66]. QUIN can directly interact with free iron ions to form
toxic complexes that exacerbate ROS formation, oxidative stress and excitotoxicity. An intrastriatal
injection of this compound causes axon-sparing neuronal lesion and mimics the pathological and
motor characteristics of Huntington’s disease (HD) [83]. In addition to NMDA receptor agonism,
it also induces lipid peroxidation [84], produces ROS, increases iNOS expression, decreases SOD
activity and causes mitochondrial dysfunction [59]. OUIN was reported to amplify inflammation by
upregulating several chemokine receptors expression in human foetal astrocytes and was comparable
to those induced by TNFα or IFNγ [85].
15. XA and Cinnabarinic Acid
Some recent studies have suggested that two lesser known intermediates of the KYN pathway, XA
and cinnabarinic acid (derived from 3-OH-KYN and 3-OH-AA, respectively), can affect brain function
and neurotransmission and interact with metabotropic glutamate (mGlu) receptors. Cinnabarinic acid
behaves as an agonist at mGlu4 receptors, while XA does likewise at mGlu2 and mGlu3 receptors.
Cinnabarinic acid is thought to play a major role in neuroinflammation and acts as a link between the
immune system and the central nervous system. XA has potential implications in the pathophysiology
of schizophrenia [86].
16. The Role of Kynurenine Metabolites in Immunoregulation
During ageing, and in many age-associated disorders like obesity, dyslipidaemia, hypertension,
insulin resistance and neurodegenerative diseases, a low-grade, Th-1-type sustained inflammation
and upregulation of IDO has been reported [87]. This results in the activation of the immune system,
and the release of proinflammatory cytokines. IFNγ is able to induce IDO (and KMO, KYNU along
with 3-OH-AAO) expression in peripheral blood monocytes but not in lymphocytes, with a marked
increase in QUIN concentrations and neopterin, a marker of Th1 immune response. QUIN can attain
neurotoxic levels, thus QUIN is able to exert neurotoxic actions [57]. Moreover, as the expression
of KMO is also induced, levels of 3-OH-AA and AA are chronically elevated as well, the former
having a ROS generating, inflammatory and neurotoxic effect. Age-associated cortisol production
also upregulates the other TRP-metabolising enzyme, TDO, resulting in elevated blood KYN and
upregulation of the pathway [88]. Some immunological effects of IDO and several KYN pathway
metabolites are summarized in Table 2.
Summary: the KYN pathway enzymes and metabolites possess a prominent immunoregulatory
role. IDO has been shown to be a central regulator of immune responses in a broad range of
physiological and pathological settings. This enzyme is upregulated both under infectious and
autoimmune inflammatory conditions, while the TRP downstream catabolites serve as a negative
feedback loop by weakening the activated immune system through several actions, including a decline
of the Th1 response and an enhancement of the Th2 type processes. It may be concluded that IDO
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has a prominent immunosuppressive property, which could theoretically be utilised in the treatment
of autoimmune diseases; however, its multiple effects, including the elevation of several neurotoxic
intermediates, can counterbalance its beneficial effects. What is more, its overactivation in several
tumours allows malignant cells to evade eradication by the immune system.
Table 2. Some immunological effects of IDO and kynurenine intermediates [57,70,72,89–91].
IDO or Kynurenine
Metabolites Effect on the Immune System (Mostly Mediated by AhR Activation)
IDO role in immunoregulation during infection, autoimmunity, pregnancy,transplantation and neoplasia
IDO activation [70,89]
• Elevated levels of kynurenine metabolites, among others QUIN with its
neurotoxic and ROS-generating properties
• TRP depletion
• decreased production of serotonin
• Antimicrobial effects (TRP depletion, potentiation of polymorphonuclear
cell function)
• Immunotolerance via TRP depletion in the microenvironment—with
suppression of antigen-specific T-cells and/or preferential apoptosis of helper
T lymphocytes (by some KYN-downstream products)
• The generation of forkhead box P3-positive (FOXP3) regulatory T cells
(Treg)—inhibition of both Th1 and Th2 cell response to regain balance
• The enhancement of TGFβ-mediated T cell differentiation (Treg); the shift of
dendritic cells to become tolerogenic
• Immunosuppression during pregnancy
• The inhibition of Th1 cell responses and selective support of Th2 actions
L-KYN/KYNA
blockage of antigens-driven specific T-cell proliferation,
induction of T-cell death
the reduction of IL-4 release (inducer of Th2 type reaction) from iNKT (invariant
natural killer T cell) cells via GPR35 activation [90]
the inhibition of LPS-induced TNF-α secretion in peripheral blood mononuclear
cells via GPR35 receptor activation [72]; and also on CD14+ peripheral blood
monocytes [57,91]);
• the attenuation of the proinflammatory cytokine HMGB1 (high-mobility
group box protein 1) of peripheral blood monocytes and of
• the release of defensin-α (also known a as HNP1-3 being an
immunomodulatory peptide, taking part in microbial killing) from
neutrophils [91];
the suppression of and proapoptotic action on natural killer cells (NK) (which also
play a role in the immunosurveillance of cancer cells)
3-OH-AA and QUIN the selective apoptosis of Th1 helper cells, promoting the proliferation of Th2 cells
QUIN increase in MCP-1 expression (a strong chemoattractant for monocytes in the brain).
17. Kynurenines during Ageing
Perturbations in the KYN pathway have been linked to ageing and various age-related diseases,
including neurodegenerative disorders (HD, AD, PD), diabetes, depression, cancer and several
cardiovascular conditions. The majority of the cardiovascular diseases are thought to be associated with
insulin resistance, the pathogenesis of which also involves an altered kynurenine pathway metabolism
sometimes together with a shortage of vitamin B6 that can exacerbate these pathologies [92] (Table 3).
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Table 3. Alterations in the kynurenine pathway in some disorders in humans.
Diseases Alteration Refs.
Neurodegenerative
diseases
Parkinson’s disease ↓ KYNA↑ 3-OH-KYN in brain [93]
Alzheimer disease upregulation of IDO1; ↑ QUIN in the brain; ↑ KYNAin putamen and caudate nuclei [80,94]
Amyotrophic lateral
sclerosis
in serum, CSF: ↑ TRP, ↑ L-KYN, ↑ QUIN;
in serum: ↓ PA [95]
Huntington’s disease early phase: ↑ QUIN, 3-OH-KYN, 3-OH-AO activity;↓ KYNA, KATs activities in the brain [70,96]
Neurovascular
diseases Ischemic stroke ↓ TRP, ↑ KYN/TRP ratio in serum [97,98]
Cancer
↑ KYN levels can increase the proliferation and
invasion of cancer cells
↑ QPRT activity in some cancer→ longer survival of
tumour cells→ worse prognosis
[59,99]
Cardiovascular
diseases
Atherogenesis Contradictory, further investigations are needed toelucidate the role of IDO in atherogenesis [100]
Cardiac arrest ↑ kynurenines predicted the risk of acute myocardialinfarction in patients with stable angina pectoris [101]
Hypertension TRP catabolites might have a role in the regulation ofblood pressure [102,103]
Psychiatric diseases
Schizophrenia
↑ KYNA in CSF, post-mortem tissues;
↓ KYNA, KYNA/KYN, KYNA/3-OH-KYN and
3-OH-KYN in blood
[104,105]
Depression ↑ KYN and QUIN in CSF;↓ SER synthesis ↑KYNA in the brain [88,106]
18. Diabetes
Low-grade inflammation caused by pro-inflammatory cytokines and/or stress hormones induce
the expression of both TDO and IDO, thereby elevating levels of downstream products, and the
availability of piridoxal-5-phosphate (activated vitamin B6) becomes limited. KYNU, the most sensitive
enzyme of the pathway against decreased vitamin B6, will not function properly, leading to a shift of the
3-OH KYN metabolism from the formation of NAD+ to the production of KYNA and XA [60,92]. These
TRP metabolites halt proinsulin synthesis and insulin release from pancreatic islets [107]; moreover, XA
binds to circulating insulin that have a 40% lower activity rate than pure insulin. The pharmacological
correction of the TRP catabolic pathway as well as maintenance of an adequate vitamin B6 status
may contribute to the prevention of insulin resistance and associated diseases. The age-associated
elevation of QUIN and neopterin, an inflammatory marker (monocyte-derived marker of a Th1 type
immune response) in the cerebrospinal fluid of a cohort of healthy women, was reported to result in
a generalized state of increased inflammation of the brain with an accompanying increased level of
general oxidative stress [108]. Thus, elevated cerebral QUIN levels can contribute to a chronic cerebral
inflammatory state as well as to longstanding glutamate receptor overactivation—both mechanisms
that are known to play significant roles in the pathomechanism of neurodegenerative disorders.
However, the age-associated rise in central levels of the KYNA derivate called quinaldic acid may be
associated with late onset diabetes, as this compound is known to be a potent diabetogenic agent [109].
19. Cardiovascular Diseases
Activated KYN pathway metabolism may play a role in atherogenesis. At this time, the findings
seem contradictory. It was reported that elevation of 3-OH-AA or AA by IDO upregulation inhibited
vascular inflammation and atherogenesis in hypercholesterolemic, low-density lipoprotein receptor-
deficient mice [100], and it was suggested that accumulation of 3-OH-AA may inhibit atherosclerosis.
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However, there are also findings that suggest the opposite, namely that IDO deficiency may be
protective against it. Further investigations are needed to elucidate the role of IDO in atherogenesis.
As for cardiac arrest, the early activation of the KYN pathway after an attack proved to be an
independent predictor of survival, although elevated levels of kynurenines predicted the risk of
acute myocardial infarction in patients with stable angina pectoris [101]. KYN has been shown to dilate
pre-constricted coronary arteries in animal models. Intravenous administration of KYN decreased the
mean arterial blood pressure in spontaneous hypertensive rats [102]. A peripherally administered
low dose of L-KYN (0.3, 1, and 3 mg/kg) to conscious rabbits increased cortical cerebral blood flow
under normal conditions and in a global ischemia model. It was suggested that the cCBF-enhancing
effect of l-KYN might be mediated by the activation of cholinergic and nitric oxide pathways [103].
Available data suggest that TRP catabolites might have a role in the regulation of blood pressure, but
more studies are required to elucidate their precise role.
It may be concluded that kynurenines have diverse effects on cardiovascular diseases and better
knowledge of these alterations may offer hope for future pharmacological interventions.
20. Cancer
IDO, TDO and AhRs are present in some tumour cells. High KYN levels can increase the proliferation
and invasion of cancer cells by dampening immunoactivity and thus affording immunotolerance by
binding to AhRs present in cancer cells [99]. AhR activation suppresses effector T cells and increases
immune tolerance by targeting dendritic and regulatory B cells [110]. The activity of QPRT in some cancer
cells is elevated, which catalyses the formation of NAD+ from QUIN, thereby diminishing oxidative stress
and leading to a longer survival of tumour cells, which implies a worse prognosis [59]. Pharmacological
inhibition of the KYN pathway in malignant tumours looks promising as their recognition by the immune
system would improve at the same time as the supply of cancer cells by NAD, would be insufficient.
21. Depression
Depression is associated with the dysregulation of the glucocorticoid axis, which results in
elevated cortisol levels and glucocorticoid receptor resistance. IDO is activated and leads to enhanced
formation of KYN metabolites. In fact, increased KYN and QUIN levels have been reported in
cerebrospinal fluid. The reduced TRP availability leads to diminished SER synthesis, which is clinically
associated with depressive symptoms, including cognitive disturbances, presumably caused by
reduced NMDA receptor activity in the hippocampus induced by elevated brain KYNA levels [88,106].
22. Neurodegenerative Diseases
The pathomechanism of HD is supposed to involve NMDA receptor mediated excitotoxicity,
which is induced by a mutant huntingtin protein, modified TRP metabolism and mitochondrial
dysfunction. Elevated QUIN, 3-OH-KYN and 3-OH-AO activity has been reported in the brains of
patients with early stage HD. Levels of these metabolites were 3- to 4-fold above the normal level [96].
In a transgenic mouse model of HD, there was also a substantial increase in the activity of KMO,
the biosynthetic enzyme of 3-OH-KYN, and a significant reduction in the activity of its degradative
enzyme, KYNU [111]. However, brain KYNA content and activities of KATs were decreased in patients
with HD [70]. To ameliorate brain QUIN and 3-OH-KYN content, KMO inhibitors might be potential
therapeutic targets for the treatment of HD and AD [112].
AD is the most common cause of dementia. The most common symptom of the disease is
memory impairment, which is in line with the preferential atrophies of temporal lobes containing the
hippocampal formations that are responsible for memory formation. NMDA receptors are abundant
here, and glutamate neurotransmission constitutes the basis of memory acquisition. The accumulation
of amyloid-β in AD brains has several toxic effects that involve mitochondrial arrest, the generation of
ROS, proteasomal dysfunction and IDO induction, among others [85]. The upregulation of IDO1 and
enhanced production of QUIN in the AD brain [80], and, interestingly, elevated KYNA concentrations
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in putamen and caudate nuclei of AD patients have also been reported [94]. The latter may be
a compensatory mechanism for counteracting QUIN effects and may contribute to the cognitive
decline by its inhibitory action at NMDA receptors.
PD is characterised by slowness of movement, rigidity and several vegetative and psychic
symptoms. Pathologically, the degeneration of neurons in the substantia nigra and a consequent
decrease in dopaminergic neurotransmission in the nigrostriatal tracts, along with the characteristic
Lewy bodies containing a toxic protein, α-synuclein, are the hallmarks of the disease. Decreased
KYNA levels and increased 3-OH-KYN levels were found in PD brains (reviewed by [93].
Both PD and AD are accompanied by mitochondrial energy failure and exaggerated ROS
production. Deficiencies in the activities of complex I in PD and complex IV in AD are supposed to
contribute to mitochondrial disturbances. Reduced activities of several complexes can also contribute
to HD pathology.
23. Conclusions
Investigations into the multiple effects of the kynurenine pathway and its changes during ageing
have increased in recent years. The broad actions of the intermediates in brain excitation/inhibition
and their role in regulating immune responses give us the possibility to interfere with the pathological
processes in an array of age-associated diseases in the future and thereby treat these devastating
diseases and perhaps prolong the lifespan of the sufferers.
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Abbreviations
3-OH-AA 3-hydroxyanthranilic acid
3-OH-AAO 3-hydroxyanthranilic acid oxygenase
3-OH-KYN 3-hydroxy-L-kynurenine
5-OH-TRP 5-hydroxy-tryptophan
5-hydroxy tryptamine serotonin
AA anthranilic acid
acetyl-CoA acetyl-coenzyme A
AD Alzheimer’s disease
AhR aryl hydrocarbon receptor
BER base excision repair
CSF cerebrospinal fluid
DSB double strand break
ETC electron transport chain
HD Huntington’s disease
HR homologous recombination
IDO indolamine-2,3-dioxygenases
IFN-α interferon-α
IL1 interleukin-1
iNKT invariant natural killer T cell
KAT kynurenine aminotransferase
KMO kynurenine-3-monooxygenase
KYNU kynureninase
KYN kynurenine
KYNA kynurenic acid
LPS lipopolysaccharides
L-TRP L-tryptophan
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MMR mismatch repair
NAD+ nicotinamide-adenine dinucleotide
NMDA N-methyl-D-aspartate
NMN nicotinate mononucleotide
NER nucleotide excision repair
NHEJ non-homologous end joining
PA picolinic acid
PD Parkinson’s disease
PARG poly(ADP-ribose) glycohydrolase
PARP poly (ADP-ribose) polymerase
PGC-1α oeroxisome proliferator-activated receptor-gamma (PPARγ) coactivator 1-alpha
QPRT quinolinic acid phosphoribosyl transferase
QUIN quinolinic acid
ROS reactive oxygen species
SER serotonin
SSB single strand break
TDO TRP-2,3-dioxygenase
TGFβ transforming growth factor-β
TNF-α tumour necrosis factor-α
TRP tryptophan
XA xanturenic acid
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